This Article Full Text Full Text (PDF) All Versions of this Article: 26/10/2208    most recent 26/9/e133 01.ATV.0000236203.90331.d0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujita, M. Articles by Kitakaze, M. Search for Related Content PubMed PubMed Citation Articles by Fujita, M. Articles by Kitakaze, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections ACE/Angiotension receptors Cell signalling/signal transduction Hypertrophy Other Vascular biology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2208.)
© 2006 American Heart Association, Inc.

Vascular Biology

Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation End Products in Human Endothelial Cells

Masashi Fujita; Hiroko Okuda; Osamu Tsukamoto; Yoshihiro Asano; Yulin Liao; Akio Hirata; Jiyoong Kim; Takeshi Miyatsuka; Seiji Takashima; Tetsuo Minamino; Hitonobu Tomoike; Masafumi Kitakaze
Objectives— Receptors for advanced glycation end products (RAGEs) play crucial roles in atherogenesis. Because tumor necrosis factor (TNF) is expressed and upregulates RAGE expression in atherosclerotic lesions, the TNF-RAGE interaction might be involved in the inflammatory process of atherogenesis. On the other hand, an angiotensin II type-1 receptor blocker (ARB), widely used as an antihypertensive drug, has been reported to have also antiatherosclerotic effects. Thus we investigated whether an ARB exerts antiatherosclerotic effects via inhibiting the TNF-RAGE interaction.

Methods and Results— Stimulation of human endothelial cells with candesartan as well as olmesartan decreased TNF-induced RAGE expression in both mRNA and protein levels along with the decrease in the activity of nuclear factor B and the expression of inflammatory mediators such as vascular cell adhesion molecule (VCAM)-1. Both candesartan and olmesartan inhibited the binding of nuclear factor B to the RAGE gene promoter. Furthermore, gene silencing of RAGE by RNA interference decreased the expression of TNF-induced VCAM-1 in both mRNA and protein levels.

Conclusions— RAGE contributes at least partially to the TNF-induced VCAM-1 expression in both mRNA and protein levels. Blockade of angiotensin II receptors might exert antiatherosclerotic effects via reducing TNF-RAGE interaction.

Key Words: angiotensin II type-1 receptor blocker (ARB) • receptors for advanced glycation end products (RAGEs) • endothelial cell

This article has been cited by other articles:

				F. Jaffre, P. Bonnin, J. Callebert, H. Debbabi, V. Setola, S. Doly, L. Monassier, B. Mettauer, B. C. Blaxall, J.-M. Launay, et al. Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy Circ. Res., January 2, 2009; 104(1): 113 - 123. [Abstract] [Full Text] [PDF]

				W. B.W.H. Melenhorst, G. M. Mulder, Q. Xi, J. G.J. Hoenderop, K. Kimura, S. Eguchi, and H. van Goor Epidermal Growth Factor Receptor Signaling in the Kidney: Key Roles in Physiology and Disease Hypertension, December 1, 2008; 52(6): 987 - 993. [Full Text] [PDF]

				K. D. Rodland, N. Bollinger, D. Ippolito, L. K. Opresko, R. J. Coffey, R. Zangar, and H. S. Wiley Multiple Mechanisms Are Responsible for Transactivation of the Epidermal Growth Factor Receptor in Mammary Epithelial Cells J. Biol. Chem., November 14, 2008; 283(46): 31477 - 31487. [Abstract] [Full Text] [PDF]

				J. Su, P. A. Lucchesi, R. A. Gonzalez-Villalobos, D. I. Palen, B. M. Rezk, Y. Suzuki, H. A. Boulares, and K. Matrougui Role of Advanced Glycation End Products With Oxidative Stress in Resistance Artery Dysfunction in Type 2 Diabetic Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1432 - 1438. [Abstract] [Full Text] [PDF]

				F. Tabet, E. L. Schiffrin, G. E. Callera, Y. He, G. Yao, A. Ostman, K. Kappert, N. K. Tonks, and R. M. Touyz Redox-Sensitive Signaling by Angiotensin II Involves Oxidative Inactivation and Blunted Phosphorylation of Protein Tyrosine Phosphatase SHP-2 in Vascular Smooth Muscle Cells From SHR Circ. Res., July 18, 2008; 103(2): 149 - 158. [Abstract] [Full Text] [PDF]

				S. Eguchi Triple Twist Theory of Rho Inhibition by the Angiotensin II Type 2 Receptor Circ. Res., May 23, 2008; 102(10): 1143 - 1145. [Full Text] [PDF]

				H. Zhang, S. W. Sunnarborg, K. K. McNaughton, T. G. Johns, D. C. Lee, and J. E. Faber Heparin-Binding Epidermal Growth Factor-Like Growth Factor Signaling in Flow-Induced Arterial Remodeling Circ. Res., May 23, 2008; 102(10): 1275 - 1285. [Abstract] [Full Text] [PDF]

				H. Nakashima, G. D. Frank, H. Shirai, A. Hinoki, S. Higuchi, H. Ohtsu, K. Eguchi, A. Sanjay, M. E. Reyland, P. J. Dempsey, et al. Novel Role of Protein Kinase C-{delta} Tyr311 Phosphorylation in Vascular Smooth Muscle Cell Hypertrophy by Angiotensin II Hypertension, February 1, 2008; 51(2): 232 - 238. [Abstract] [Full Text] [PDF]

				G. Ding, A. Zhang, S. Huang, X. Pan, G. Zhen, R. Chen, and T. Yang ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1889 - F1897. [Abstract] [Full Text] [PDF]